Exozymes Inc. SEC filings EXOZ
Exozymes Inc. has 128 filings in SEC EDGAR's recent list, going back to Feb 9, 2024. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 9, 2026 | Oct 9, 2026 |
| DEFA14A | Additional proxy material | Sep 28, 2026 | — |
| DEF 14A | Proxy statement | Sep 28, 2026 | Nov 13, 2026 |
| 8-K |
Current report
Other events
|
Sep 18, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 1, 2026 | Jun 30, 2026 |
| 424B5 | Prospectus supplement | Jun 30, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 8, 2026 | Jun 5, 2026 |
| 424B5 | Prospectus supplement | Jun 8, 2026 | — |
| 424B5 | Prospectus supplement | Jun 4, 2026 | — |
| 424B5 | Prospectus supplement | May 29, 2026 | — |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Other events
|
Apr 10, 2026 | Apr 10, 2026 |
| 424B5 | Prospectus supplement | Apr 9, 2026 | — |
| 8-K |
Current report
Other events
|
Mar 31, 2026 | Mar 30, 2026 |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Other events
|
Feb 5, 2026 | Jan 29, 2026 |
| 424B2 | Prospectus | Jan 26, 2026 | — |
| EFFECT | Filing | Jan 23, 2026 | — |
| CORRESP | Letter to the SEC | Jan 22, 2026 | — |
| S-3 | Shelf registration | Jan 16, 2026 | — |
| S-8 | Employee stock plan registration | Dec 16, 2025 | — |
| DRS | Filing | Dec 15, 2025 | — |
| 8-K |
Current report
Other events
|
Dec 12, 2025 | Dec 11, 2025 |
| 8-K |
Current report
Other events
|
Nov 13, 2025 | Nov 13, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Other events
|
Oct 3, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 28, 2025 | Jul 25, 2025 |
| 424B3 | Prospectus | Jul 8, 2025 | — |
| 8-K |
Current report
Other events
|
Jul 8, 2025 | Jul 7, 2025 |
| 8-K |
Current report
Material agreement
|
Jun 26, 2025 | Jun 26, 2025 |
| DEFR14A | Filing | Jun 23, 2025 | — |
| DEF 14A | Proxy statement | Jun 20, 2025 | Jul 25, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 20, 2025 | Jun 17, 2025 |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| S-8 | Employee stock plan registration | Apr 25, 2025 | — |
| 424B3 | Prospectus | Apr 7, 2025 | — |
| 8-K |
Current report
Other events
|
Apr 2, 2025 | Apr 2, 2025 |
| 8-K |
Current report
Other events
|
Apr 2, 2025 | Apr 2, 2025 |
| 424B3 | Prospectus | Apr 1, 2025 | — |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 21, 2025 | Feb 17, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 11, 2025 | Feb 10, 2025 |
| D | Filing | Nov 19, 2024 | — |
| 8-K |
Current report
Material agreement, Other events
|
Nov 18, 2024 | Nov 14, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 424B4 | Prospectus | Nov 12, 2024 | — |
| 424B4 | Prospectus | Nov 12, 2024 | — |
| CERT | Filing | Nov 12, 2024 | — |
| EFFECT | Filing | Nov 8, 2024 | — |
| CORRESP | Letter to the SEC | Nov 6, 2024 | — |
| CORRESP | Letter to the SEC | Nov 6, 2024 | — |
| CORRESP | Letter to the SEC | Oct 31, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 30, 2024 | — |
| CORRESP | Letter to the SEC | Oct 25, 2024 | — |
| S-1/A | Amended registration statement | Oct 21, 2024 | — |
| CORRESP | Letter to the SEC | Oct 9, 2024 | — |
| CORRESP | Letter to the SEC | Oct 7, 2024 | — |
| CORRESP | Letter to the SEC | Oct 7, 2024 | — |
| S-1/A | Amended registration statement | Oct 4, 2024 | — |
| CORRESP | Letter to the SEC | Sep 26, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2024 | — |
| CORRESP | Letter to the SEC | Sep 19, 2024 | — |
| S-1/A | Amended registration statement | Sep 19, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2024 | — |
| FWP | Free writing prospectus | Sep 11, 2024 | — |
| CORRESP | Letter to the SEC | Sep 6, 2024 | — |
| S-1/A | Amended registration statement | Sep 6, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2024 | — |
| 8-A12B | Filing | Aug 1, 2024 | — |
| S-1/A | Amended registration statement | Aug 1, 2024 | — |
| FWP | Free writing prospectus | May 30, 2024 | — |
| CORRESP | Letter to the SEC | May 22, 2024 | — |
| S-1/A | Amended registration statement | May 22, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2024 | — |
| CORRESP | Letter to the SEC | Apr 17, 2024 | — |
| S-1/A | Amended registration statement | Apr 17, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2024 | — |
| S-1/A | Amended registration statement | Feb 14, 2024 | — |
| S-1 | Registration statement | Feb 9, 2024 | — |
Showing 84 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXOZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Monrovia, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2010788
- Former names
- Invizyne Technologies Inc (until Jan 21, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.